Hongyang Pi1, Chad M Kosanovich1, Adam Handen2, Michael Tao1, Jacqueline Visina3, Gabrielle Vanspeybroeck1, Marc A Simon4, Michael G Risbano5, Aken Desai6, Michael A Mathier4, Belinda N Rivera-Lebron5, Quyen Nguyen5, Jennifer Kliner4, Mehdi Nouraie7, Stephen Y Chan8. 1. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 2. Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Pittsburgh, PA. 3. Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 4. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Pittsburgh, PA; Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 5. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Pittsburgh, PA; Division of Pulmonary, Allergy and Critical Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 6. Division of Cardiovascular Medicine, University of Colorado, Aurora, CO. 7. Division of Pulmonary, Allergy and Critical Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 8. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Pittsburgh, PA; Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. Electronic address: chansy@pitt.edu.
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressures and is managed by vasodilator therapies. Current guidelines encourage PAH management in specialty care centers (SCCs), but evidence is sparse regarding improvement in clinical outcomes and correlation to vasodilator use with referral. RESEARCH QUESTION: Is PAH management at SCCs associated with improved clinical outcomes? STUDY DESIGNAND METHODS: A single-center, retrospective study was performed at the University of Pittsburgh Medical Center (UPMC; overseeing 40 hospitals). Patients with PAH were identified between 2008 and 2018 and classified into an SCC or non-SCC cohort. Cox proportional hazard modeling was done to compare for all-cause mortality, as was negative binomial regression modeling for hospitalizations. Vasodilator therapy was included to adjust outcomes. RESULTS: Of 580 patients with PAH at UPMC, 455 (78%) were treated at the SCC, comprising a younger (58.8 vs 64.8 years; P < .001) and more often female (68.4% vs 51.2%; P < .001) population with more comorbidities without differences in race or income. SCC patients demonstrated improved survival (hazard ratio, 0.68; P = .012) and fewer hospitalizations (incidence ratio, 0.54; P < .001), and provided more frequent disease monitoring. Early patient referral to SCC (< 6 months from time of diagnosis) was associated with improved outcomes compared with non-SCC patients. SCC patients were more frequently prescribed vasodilators (P < .001) and carried more diagnostic PAH coding (P < .001). Vasodilators were associated with improved outcomes irrespective of location but without statistical significance when comparing between locations (P > .05). INTERPRETATION: The UPMC SCC demonstrated improved outcomes in mortality and hospitalizations. The SCC benefit was multifactorial, with more frequent vasodilator therapy and disease monitoring. These findings provide robust evidence for early and regular referral of patients with PAH to SCCs.
BACKGROUND:Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressures and is managed by vasodilator therapies. Current guidelines encourage PAH management in specialty care centers (SCCs), but evidence is sparse regarding improvement in clinical outcomes and correlation to vasodilator use with referral. RESEARCH QUESTION: Is PAH management at SCCs associated with improved clinical outcomes? STUDY DESIGNAND METHODS: A single-center, retrospective study was performed at the University of Pittsburgh Medical Center (UPMC; overseeing 40 hospitals). Patients with PAH were identified between 2008 and 2018 and classified into an SCC or non-SCC cohort. Cox proportional hazard modeling was done to compare for all-cause mortality, as was negative binomial regression modeling for hospitalizations. Vasodilator therapy was included to adjust outcomes. RESULTS: Of 580 patients with PAH at UPMC, 455 (78%) were treated at the SCC, comprising a younger (58.8 vs 64.8 years; P < .001) and more often female (68.4% vs 51.2%; P < .001) population with more comorbidities without differences in race or income. SCCpatients demonstrated improved survival (hazard ratio, 0.68; P = .012) and fewer hospitalizations (incidence ratio, 0.54; P < .001), and provided more frequent disease monitoring. Early patient referral to SCC (< 6 months from time of diagnosis) was associated with improved outcomes compared with non-SCCpatients. SCCpatients were more frequently prescribed vasodilators (P < .001) and carried more diagnostic PAH coding (P < .001). Vasodilators were associated with improved outcomes irrespective of location but without statistical significance when comparing between locations (P > .05). INTERPRETATION: The UPMCSCC demonstrated improved outcomes in mortality and hospitalizations. The SCC benefit was multifactorial, with more frequent vasodilator therapy and disease monitoring. These findings provide robust evidence for early and regular referral of patients with PAH to SCCs.
Authors: Olivier Sitbon; Raymond L Benza; David B Badesch; Robyn J Barst; C Gregory Elliott; Virginie Gressin; Jean-Christophe Lemarié; Dave P Miller; Erwan Muros-Le Rouzic; Gérald Simonneau; Adaani E Frost; Harrison W Farber; Marc Humbert; Michael D McGoon Journal: Eur Respir J Date: 2015-04-02 Impact factor: 16.671
Authors: Raymond L Benza; Mardi Gomberg-Maitland; Dave P Miller; Adaani Frost; Robert P Frantz; Aimee J Foreman; David B Badesch; Michael D McGoon Journal: Chest Date: 2011-06-16 Impact factor: 9.410
Authors: M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau Journal: Eur Respir J Date: 2010-06-18 Impact factor: 16.671
Authors: Chad M Kosanovich; Hongyang Pi; Adam Handen; Erin Schikowski; Yimin Chen; Floyd W Thoma; Suresh Mulukutla; Steve Koscumb; Mehdi Nouraie; Stephen Y Chan Journal: Pulm Circ Date: 2022-06-07 Impact factor: 2.886
Authors: Barry J Maron; Martin S Maron; Mathew S Maurer; Ethan J Rowin; Bradley A Maron; Nazzareno Galiè Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501
Authors: Hilary M DuBrock; Charles D Burger; Sonja D Bartolome; Jeremy P Feldman; D Dunbar Ivy; Erika B Rosenzweig; Jeffrey S Sager; Kenneth W Presberg; Stephen C Mathai; Matthew R Lammi; James R Klinger; Michael Eggert; Teresa De Marco; Jean M Elwing; David Badesch; Todd M Bull; Linda M Cadaret; Gautam Ramani; Thenappan Thenappan; H James Ford; Nadine Al-Naamani; Marc A Simon; Sula Mazimba; James R Runo; Murali Chakinala; Evelyn M Horn; John J Ryan; Robert P Frantz; Michael J Krowka Journal: Pulm Circ Date: 2021-05-17 Impact factor: 3.017